688089.SH
ST嘉必优
SSE · Healthcare · Biotechnology · CN
CNY 7.56
+0.67%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 418.2M | 563.1M | 555.6M | 443.8M | 433.4M |
| Cost of Revenue | 236.7M | 294.5M | 313.3M | 255.6M | 250.8M |
| Gross Profit | 181.5M | 268.6M | 242.3M | 188.2M | 182.7M |
| Operating Expenses | |||||
| R&D Expense | 48.7M | 47.4M | 47.9M | 38.6M | 32.3M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 46.6M | 43.7M | 40.5M | 25.9M | 39.5M |
| Selling & Marketing Expense | 23.2M | 24.4M | 31.8M | 30.4M | 24.8M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 128.1M | 120.6M | 121.6M | 98.9M | 85.9M |
| Cost and Expenses | 364.8M | 415.1M | 434.9M | 354.5M | 336.6M |
| Operating Income (EBIT) | 56.0M | 149.5M | 126.5M | 81.6M | 51.1M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 65.4M | 162.3M | 139.8M | 100.0M | 78.1M |
| Income Tax Expense | 15.7M | 23.0M | 19.7M | 13.6M | 16.6M |
| Bottom Line | |||||
| Net Income | 55.2M | 143.7M | 124.2M | 91.4M | 64.4M |
| Earnings from Cont. Ops | 49.8M | 139.3M | 120.1M | 86.4M | 61.6M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 55.2M | 143.7M | 124.2M | 91.4M | 64.4M |
| Per Share | |||||
| Basic EPS | CN¥0.33 | CN¥0.86 | CN¥0.74 | CN¥0.54 | CN¥0.38 |
| Diluted EPS | CN¥0.33 | CN¥0.86 | CN¥0.74 | CN¥0.54 | CN¥0.38 |
| Revenue Per Share | CN¥2.50 | CN¥3.37 | CN¥3.31 | CN¥2.62 | CN¥2.56 |
| Shares | |||||
| Basic Shares Outstanding | 167.6M | 167.1M | 167.9M | 169.2M | 169.4M |
| Diluted Shares Outstanding | 167.6M | 167.1M | 167.9M | 169.2M | 169.4M |
| Profitability Metrics | |||||
| EBITDA | — | 212.5M | 183.9M | 130.4M | 77.7M |
| D&A | — | 63.0M | 57.4M | 48.8M | 26.6M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026